Chronic Myeloid Leukemia Coverage from Every Angle

Recent News

EHA25 Virtual: Nilotinib Induction Therapy for Chronic Phase CML
EHA25 Virtual: Extended Follow-up on Early Switch From Imatinib to Dasatinib in CML
AACR II: Race-Based Survival Differences in Patients With CML Living in Texas
EHA25 Virtual: Nilotinib in Patients With CML Who Relapse After Discontinuing Imatinib
ASCO20: Are Providers Following Practice Guidelines for Discontinuation of TKIs?
EHA25 Virtual: Dose Reduction of Second-Generation TKIs in CML
EHA25 Virtual: Low-Dose Ponatinib for Patients With CML
Identifying Key Regulating Proteins in CML With CRISPR Technology
ASCO20: Long-Term Study Update on Bosutinib for Imatinib-Resistant CML
ASCO 2020: Early Results of Ponatinib Dose-Range Study in CML
ASCO20: Bosutinib for Patients With TKI-Intolerant CML
Is TKI Type Linked to Treatment-Free Remission in Patients With CML?
Use of Live Attenuated Vaccines in Teenagers Treated With Imatinib for CML
TKI Therapy for CML and Cardiovascular Adverse Events
Nilotinib for Chronic Phase CML: Japanese Dose-Escalation Study
Considerations for Using Tyrosine Kinase Inhibitors in CML During the COVID‐19 Pandemic
DDW 2020: Platelet Threshold and Adverse Events After Endoscopy in SCT Recipients
Combining Venetoclax and TKI in Ph-Positive Advanced Myeloid Leukemias
Long-Term Survival Outcomes With Front-Line Dasatinib in CML
Body Mass Index and Dasatinib for Chronic Phase CML
How COVID-19 May Affect Patients on TKI Therapy for Chronic Myeloid Leukemia
CML and COVID-19: ASH Offers Answers to Frequently Asked Questions
Ruxolitinib for Rare BCR-ABL1–Negative Myeloid Neoplasms
2020 CML Treatment Recommendations From European LeukemiaNet
TAT 2020: Adding Diabetes Drug to Imatinib Therapy for CML
Characterizing a Regulatory Axis in CML Cell Apoptosis
Common Clover Plant May Harbor Anti-CML Compounds
Can TKIs Combined With Interferon-α Enhance Immunosuppressive State in CML?
Effect of Hydroxyurea and Imatinib on Major Molecular Response in CML
Genetic Mutations in CML and Predicting Response to TKI Therapy
Early Detection of Kinase Domain Mutations in Chronic Phase CML
Nilotinib Plus Pegylated Interferon in First-Line Treatment of CML
Minimum Effective Dose of Second-Line Bosutinib in Elderly Patients With CML
Is Pregnancy Safe for Patients Under Treatment for CML?
Real-World Ponatinib Outcomes in Patients With CML From Nationwide Belgian Registry
Immunologic Identifiers May Be Related to Relapse in Chronic Myeloid Leukemia

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.